Molecular Imaging and Radionuclide Therapy (formerly Turkish Journal of Nuclear Medicine) is the official publication of Turkish Society of Nuclear Medicine.

**Focus and Scope**
Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is a double-blind peer-review journal published in English. It publishes original research articles, invited reviews, editorials, short communications, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology. MIRT is published three times a year (February, June, October). Audience: Nuclear medicine physicians, medical physicists, radiopharmaceutical scientists, radiobiologists.


Molecular Imaging and Radionuclide Therapy is indexed in Pubmed, Pubmed Central (PMC), Emerging Sources Citation Index (ESCI), TUBITAK-ULAKBIM, DOAJ, Scopus, Gale/Cengage Learning, EBSCO databases, Embase, ProQuest Health & Medical Complete, CINAHL, Index Copernicus, J-Gate, IdealOnline, ROOT INDEXING, Türkiye Atf Dizini-Türkiye Citation Index, Turk Medline, EuroPub, Hinari, GOALI, ARDI, OARE and AGORA.

**Open Access Policy**
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Open Access Policy is based on rules of Budapest Open Access Initiative (BOAI) (http://www.budapestopenaccessinitiative.org/). By “open access” to [peer-reviewed research literature], we mean its free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself. The only constraint on reproduction and distribution, and the only role for copyright in this domain, should be to give authors control over the integrity of their work and the right to be properly acknowledged and cited.

**Subscription Information**
Manuscripts can only be submitted electronically through the Journal Agent website (http://www.journalagent.com/mirt/?plng=eng) after creating an account. This system allows online submission and review.

All published volumes in full text can be reached free of charge through the website http://mirt.tsnmjournals.org

**Copyright Statement**
Turkish Society of Nuclear Medicine holds the international copyright of all the content published in the journal. Republication and reproduction of images or tables in any published material should be done with proper citation of source providing authors names; article title; journal title; year (volume) and page of publication; copyright year of the article. The author(s) hereby affirms that the manuscript submitted is original, that all statement asserted as facts are based on author(s) careful investigation and research for accuracy, that the manuscript does not, in whole or part, infringe any copyright, that it has not been published in total or in part and is not being submitted or considered for publication in total or in part elsewhere. Completed Copyright Statement form should be submitted to the online article system.

By signing this form,
1. Each author acknowledge that he/she participated in the work in a substantive way and is prepared to take public responsibility for the work.
2. Each author further affirms that he or she has read and understands the “Ethical Guidelines for Publication of Research”.
3. The author(s), in consideration of the acceptance of the manuscript for publication, does hereby assign and transfer to the Molecular Imaging and Radionuclide Therapy all of the rights and interest in and the copyright of the work in its current form and in any form subsequently revised for publication and/or electronic dissemination.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

**Instructions for Authors**
Instructions for authors are published in the journal and on the website http://mirt.tsnmjournals.org

**Material Disclaimer**
Scientific and legal responsibilities pertaining to the papers belong to the authors. Contents of the manuscripts and accuracy of references are also the author’s responsibility. The Turkish Society of Nuclear Medicine, the Editor, the Editorial Board or the publisher do not accept any responsibility for opinions expressed in articles.

Financial expenses of the journal are covered by Turkish Society of Nuclear Medicine.

**Correspondence Address**
Editor in Chief Prof. Murat Fani Bozkurt, MD, FEBNM Hacettepe University, Medical School, Department of Nuclear Medicine, Ankara, Turkey
E-mail: fanibozkurt@gmail.com
Web page: http://mirt.tsnmjournals.org/

**Publisher Corresponding Address**
Galenos Yayinevi Tic. Ltd. Şti.
Address: Molla Gürani Mah. Kaçamak Sk. No: 21/1 34093 Fındıkzade, İstanbul, Turkey
Phone: +90 212 621 99 25
Fax: +90 212 621 99 27
E-mail: info@galenos.com.tr
INSTRUCTIONS TO AUTHORS

Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) publishes original research articles, short communications, invited reviews, editorials, case reports with a literature review on the topic, interesting images, consensus statements, guidelines, letters in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology. MIRT is published by the Turkish Society of Nuclear Medicine three times a year (February, June, October).

Molecular Imaging and Radionuclide Therapy does not charge any article submission or processing fees.

GENERAL INFORMATION

MIRT commits to rigorous peer review, and stipulates freedom from commercial influence, and promotion of the highest ethical and scientific standards in published articles. Neither the Editor(s) nor the publisher guarantees, warrants or endorses any product or service advertised in this publication. All articles are subject to review by the editors and peer reviewers. If the article is accepted for publication, it may be subjected to editorial revisions to aid clarity and understanding without changing the data presented.

Manuscripts must be written in English and must meet the requirements of the journal. The journal is in compliance with the uniform requirements for manuscripts submitted to biomedical journals published by the International Committee of Medical Journal Editors (NEJM 1997; 336:309-315, updated 2016). Manuscripts that do not meet these requirements will be returned to the author for necessary revision before the review. Authors of manuscripts requiring modifications have a maximum of two months to resubmit the revised text. Manuscripts returned after this deadline will be treated as new submissions.

It is the authors’ responsibility to prepare a manuscript that meets ethical criteria. The Journal adheres to the principles set forth in the Helsinki Declaration October 2013 (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) and holds that all reported research involving “Human beings” conducted in accordance with such principles. Reports describing data obtained from research conducted in human participants must contain a statement in the MATERIALS AND METHODS section indicating approval by the ethical review board (including the approval number) and affirmation that INFORMED CONSENT was obtained from each participant. All manuscripts reporting experiments using animals must include a statement in the MATERIALS AND METHODS section giving assurance that all animals have received humane care in compliance with the Guide for the Care and Use of Laboratory Animals (www.nap.edu) and indicating approval by the ethical review board.

If the study should have ethical approval, authors asked to provide ethical approval in order to proceed the review process. If they provide approval, review of the manuscript will continue.

In case report(s) and interesting case(s) a statement regarding the informed consent of the patients should be included in the manuscript and the identity of the patient(s) should be hidden.

Subjects must be identified only by number or letter, not by initials or names. Photographs of patients’ faces should be included only if scientifically relevant. Authors must obtain written consent from the patient for use of such photographs. In cases of image media usage that potentially expose patients’ identity requires obtaining permission for publication from the patients or their parents/guardians. If the proposed publication concerns any commercial product, the author must include in the cover letter a statement indicating that the author(s) has (have) no financial or other interest with the product or explaining the nature of any relations (including consultancies) between the author(s) and editor the manufacturer or distributor of the product.

All submissions will be screened by Crossref Similarity Check powered by “iThenticate”. Manuscripts with an overall similarity index of greater than 25%, or duplication rate at or higher than 5% with a single source will be returned back to authors.

MANUSCRIPT CATEGORIES

1. Original Articles
2. Short Communications are short descriptions of focused studies with important, but very straightforward results.
3. Reviews address important topics in the field. Authors considering the submission of uninvited reviews should contact the editor in advance to determine if the topic that they propose is of current potential interest to the Journal. Reviews will be considered for publication only if they are written by authors who have at least three published manuscripts in the international peer reviewed journals and these studies should be cited in the review. Otherwise only invited reviews will be considered for peer review from qualified experts in the area.
4. Editorials are usually written by invitation of the editor by the editors on current topics or by the reviewers involved in the evaluation of a submitted manuscript and published concurrently with that manuscript.
5. Case Report and Literature Reviews are descriptions of a case or small number of cases revealing a previously undocumented disease process, a unique unreported manifestation or treatment of a known disease process, unique unreported complications of treatment regimens or novel and important insights into a condition’s pathogenesis, presentation, and/or management. The Journal’s policy is to accept case reports only if it is accompanied by a review of the literature on the related topic. They should include an adequate number of images and figures.
6. Interesting Image

One of the regular parts of Molecular Imaging and Radionuclide Therapy is a section devoted to interesting images. Interesting image(s) should describe case(s) which are unique and include interesting findings adding insights into the interpretation of patient images, a condition’s pathogenesis, presentation, and/or management.

7. Consensus Statements or Guidelines may be submitted by professional societies. All such submissions will be subjected to peer review, must be modifiable in response to criticisms, and will be published only if they meet the Journal’s usual editorial standards.
8. Letters to the Editor may be submitted in response to work that has been published in the Journal. Letters should be short commentaries related to specific points of agreement or disagreement with the published work.

Note on Prior Publication

Articles are accepted for publication on the condition that they are original, are not under consideration by another journal, or have not been previously published. Direct quotations, tables, or illustrations that have appeared in
INSTRUCTIONS TO AUTHORS

copyrighted material must be accompanied by written permission for their use from the copyright owner and authors. Materials previously published in whole or in part shall not be considered for publication. At the time of submission, authors must report that the manuscript has not been published elsewhere. Abstracts or posters displayed at scientific meetings need not be reported.

MANUSCRIPT SUBMISSION PROCEDURES

MIRT only accepts electronic manuscript submission at the web site http://www.journalagent.com/mirt/. After logging on to the website Click the ‘online manuscript submission’ icon. All corresponding authors should be provided with a password and a username after entering the information required. If you already have an account from a previous submission, enter your username and password to submit a new or revised manuscript. If you have forgotten your username and/or password, please send an e-mail to the editorial office for assistance. After logging on to the article submission system please read carefully the directions of the system to give all needed information and attach the manuscript, tables and figures and additional documents.

All Submissions Must Include:
1. Completed Copyright Assignment & Disclosure of Potential Conflict of Interest Form; This form should be downloaded from the website (provided in the author section), filled in thoroughly and uploaded to the website during the submission.
2. All manuscripts describing data obtained from research conducted in human participants must be accompanied with an approval document by the ethical review board.
3. All manuscripts reporting experiments using animals must include approval document by the animal ethical review board.
4. All submissions must include the authorship contribution form which is signed by all authors.

Authors must complete all online submission forms. If you are unable to successfully upload the files please contact the editorial office by e-mail.

MANUSCRIPT PREPARATION

General Format
The Journal requires that all submissions be submitted according to these guidelines:
• Text should be double spaced with 2.5 cm margins on both sides using 12-point type in Times Roman font.
• All tables and figures must be placed after the text and must be labeled.
• Each section (abstract, text, references, tables, figures) should start on a separate page.
• Manuscripts should be prepared as a word document (*.doc) or rich text format (*.rtf).
• Please make the tables using the table function in Word.
• Abbreviations should be defined in parenthesis where the word is first mentioned and used consistently thereafter.
• Results should be expressed in metric units. Statistical analysis should be done accurately and with precision. Please consult a statistician if necessary.
• Authors’ names and institutions should not be included in the manuscript text and should be written only in the title page.

Title Page
The title page should be a separate form from the main text and should include the following:
• Full title (in English and in Turkish). Turkish title will be provided by the editorial office for the authors who are not Turkish speakers.
• Authors’ names and institutions.
• Short title of not more than 40 characters for page headings.
• At least three and maximum eight keywords. (in English and in Turkish). Do not use abbreviations in the keywords. Turkish keywords will be provided by the editorial office for the authors who are not Turkish speakers. If you are not a native Turkish speaker, please reenter your English keywords to the area provided for the Turkish keywords. English keywords should be provided from http://www.nlm.nih.gov/mesh (Medical Subject Headings) while Turkish keywords should be provided from http://www.bilimterimleri.com.
• Word count (excluding abstract, figure legends and references).
• Corresponding author’s e-mail and address, telephone and fax numbers.
• Name and address of person to whom reprint requests should be addressed.

Original Articles
Authors are required to state in their manuscripts that ethical approval from an appropriate committee and informed consents of the patients were obtained. Original Articles should be submitted with a structured abstract of no more than 250 words. All information reported in the abstract must appear in the manuscript. The abstract should not include references. Please use complete sentences for all sections of the abstract. Structured abstract should include background, objective, methods, results and conclusions. Turkish abstract will be provided by the editorial office for the authors who are not Turkish speakers. If you are not a native Turkish speaker, please reenter your English abstract to the area provided for the Turkish abstract.

- Introduction
- Materials and Methods
- Results
- Discussion
- Study Limitations
- Conclusion

May be given for contributors who are not listed as authors, or for grant support of the research.

References should be cited in numerical order (in parentheses) in the text and listed in the same numerical order at the end of the manuscript on a separate page or pages. The author is responsible for the accuracy of references. Examples of the reference style are given below. Further examples will be found in the articles describing the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (Ann Intern Med.1988; 208:258-265, Br Med J. 1988; 296:401-405). The titles of journals should be abbreviated according to the style used in the Index Medicus. Journal Articles and Abstracts: Surnames and initials of author’s name, title of the article, journal name, date, volume number, and pages. All authors should be listed regardless of number. The citation of unpublished papers, observations or personal communications is not permitted. Citing an abstract is not recommended. Books: Surnames and initials of author’s names, name of the book, editor’s name, book title, edition, city, publisher, date and pages.
address of the person to whom reprint requests should be directed. The manuscript when published will become the property of the journal.

Archiving
The editorial office will retain all manuscripts and related documentation (correspondence, reviews, etc.) for 12 months following the date of publication or rejection.

Submission Preparation Checklist
As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
1. The submission has not been previously published, nor is it before another journal for consideration (or an explanation has been provided in Comments to the Editor).
2. The submission file is in Microsoft Word, RTF, or WordPerfect document file format. The text is double-spaced; uses a 12-point font; employs italics, rather than underlining (except with URL addresses); and the location for all illustrations, figures, and tables should be marked within the text at the appropriate points.
3. Where available, URLs for the references will be provided.
4. All authors should be listed in the references, regardless of the number.
5. The text adheres to the stylistic and bibliographic requirements outlined in the Author Guidelines, which is found in About the Journal.
6. English keywords should be provided from http://www.nlm.nih.gov/mesh (Medical Subject Headings), while Turkish keywords should be provided from http://www.bilimterimleri.com
7. The title page should be a separate document from the main text and should be uploaded separately.
8. The “Affirmation of Originality and Assignment of Copyright/The Disclosure Form for Potential Conflicts of Interest Form” and Authorship Contribution Form should be downloaded from the website, filled thoroughly and uploaded during the submission of the manuscript.

TO AUTHORS
Copyright Notice
The author(s) hereby affirms that the manuscript submitted is original, that all statement asserted as facts are based on author(s) careful investigation and research for accuracy, that the manuscript does not, in whole or part, infringe any copyright, that it has not been published in total or in part and is not being submitted or considered for publication in total or in part elsewhere. Completed Copyright Assignment & Affirmation of Originality Form will be uploaded during submission. By signing this form:
1. Each author acknowledges that he/she participated in the work in a substantive way and is prepared to take public responsibility for the work.
2. Each author further affirms that he or she has read and understands the “Ethical Guidelines for Publication of Research”
3. The author(s), in consideration of the acceptance of the manuscript for publication, does hereby assign and transfer to the Molecular Imaging and Radionuclide Therapy all of the rights and interest in and the copyright of the work in its current form and in any form subsequently revised for publication and/or electronic dissemination.

Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

Peer Review Process
1. The manuscript is assigned to an editor, who reviews the manuscript and makes an initial decision based on manuscript quality and editorial priorities.
2. For those manuscripts sent for external peer review, the editor assigns at least two reviewers to the manuscript.
3. The reviewers review the manuscript.
4. The editor makes a final decision based on editorial priorities, manuscript quality, and reviewer recommendations.
5. The decision letter is sent to the author.

Contact Address
All correspondence should be directed to the Editorial Office:
Cinnah Caddesi Pilot Sokak No:10/12 06650 Çankaya / Ankara, Turkey
Phone: +90 312 441 00 45
Fax: +90 312 441 12 97
E-mail: info@tsnmjournals.org
Original Articles

1. The Role of ¹⁸F-FDOPA PET/CT in Recurrent Medullary Thyroid Cancer Patients with Elevated Serum Calcitonin Levels
   Mine Araz, Çigdem Soydal, Özgür Demir, Mustafa Kürşat Gökcan, Nuriye Özlem Küçük; Ankara, Turkey

8. Oxidized Regenerated Cellulose can be a Cause of False Tumor Recurrence on PET/CT in Patients with Lung Cancer Treated Surgically
   Muhammet Sayan, Ali Çelik, Merve Şarık Türk, Divilin Özkan, Irmak Akarsu, Ozan Yazıcı, Uğuray Aydos, Nilgün Yılmaz Demirci, Gülen Akyol, İsmail Cüneyt Kurul; Ankara, Turkey

13. Axillary Lymph Node Uptake on ¹⁸F-FDG PET/CT after COVID-19 Vaccination: A Direct Comparison Study with Influenza Vaccination
   Yoichi Otomi, Takayoshi Shinya, Hiroto Kasai, Naoko Okada, Tomoki Matsushita, Kohei Higashi, Saya Matsuzaki, Yuka Hiroshima, Michiko Kubo, Hideki Otsuka, Masafumi Harada; Tokushima, Japan

20. Characteristics of Radiopharmaceutical Uptake in Primary Tumor and Metastatic Lesions of Prostate Carcinoma: Comparison of Oligometastatic with Multimetastatic Disease
   Gonca Kara Gedik, Farise Yılmaz, Hasan Öner; Konya, Turkey

28. Leukocyte Labeling with Tc-99m-HMPAO: The Role of Leucocyte Numbers and Medication on the Labeling Efficacy and Image Quality
   Emre Karayel, Meltem Oacak, A. Seher Birteköz Tan; Istanbul, Turkey

35. The Impact of Metabolic ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Parameters on the Prognosis of Resectable Pancreatic Adenocarcinoma
   Özgül Ekmeççioğlu, Muhamre Battal, Özgür Bostancı, Banu Yılmaz Özgüven; Istanbul, Turkey

42. Attenuation Correction for Dedicated Cardiac SPECT Imaging Without Using Transmission Data
   Getu Ferenji Tadesse, Parham Geramifar, Mehrshad Abbasi, Eyachew Misganew Tsegaw, Mohammad Amin, Ali Salimi, Mohammad Mohammadi, Behnoosh Teimourianfard, Mohammed Reza Ay; Tehran, Iran, Addis Ababa, Debre Tabor, Ethiopia

Interesting Images

54. Metachronous Brain Tumor in 177Lu-PSMA Scan in a Patient with Metastatic Castration Resistant Prostate Cancer Mimicking Disease Progression
   Elahe Pirayesh, Mehrdad Tavakoli; Tehran, Iran
57  Findings of I-131 SPECT/CT, 18F-FDG, and 68Ga-FAPI-04 PET/CT Imaging in a Patient Treated with Radioiodine Therapy for Metastatic Papillary Thyroid Carcinoma
Radyoiyot Tedavisi Alan Metastatik Papiller Tiroid Karsinomlu Bir Hastada I-131 SPECT/IBT, 18F-FDG ve 68Ga-FAPI-04 PET/IBT Görüntülene Bulguları

Gamze Tatar, Göksel Alçın, Özge Erol Fenercioğlu, Rahime Şahin, Tevfik Fikret Çermik; İstanbul, Turkey

58  11C-Methionine PET/CT and 18F-FDG PET/CT in the Evaluation of Adult Alveolar Rhabdomyosarcoma
Erişkin Alveolar Rabdomiyosarkomun Değerlendirilmesinde 11C-Metionin PET/IBT ve 18F-FDG PET/IBT
Yuka Hiroshima, Yoichi Otomi, Takayoshi Shinya, Hideki Otsuka, Masafumi Harada; Tokushima, Japan

62  Incidental Tc-99m MDP Uptake in Cortical-subcortical Parietotemporal Cerebral Area in a Patient with a History of Recent Ischemic Cerebrovascular Event who Underwent Whole-body Bone Scan
Yakın Zamanda İskemik Serebrovasküler Olay Öyküsü Olan ve Tüm Vücut Kemik Taraması Yapılan Bir Hastada Kortikal-subkortikal Parietotemporal Serebral Alanında Tesadüfen Saptanan Tc-99m MDP Tutulumu
Demet Nak, Sibel Gökşel; Rize, Turkey

65  Incidental Detection of Pseudomembranous Colitis Through 18F-FDG PET/CT During the Restaging of Colorectal Cancer
Kolorektal Kanserinin Erevlenmesi Sırasında 18F-FDG PET/IBT ile Psödomembranöz Kollitin Tesadüfen Saptanması
Luca Filippi; Latina, Italy

68  18F-FDG PET/CT Imaging of a Grade 3 Lymphomatoid Granulomatosis in an Immunocompromised Pediatric Patient
Primer İmmün Yetmezliği Olan Evre 3 Lenfomatoid Granülomatoz Tanılı Pediatrik Bir Hastanın 18F-FDG PET/IBT Görüntülmesi
Selin Kesim, Feyza Şen, Salih Özgüven; İstanbul, Turkey

71  Incidental Detection of Pseudomembranous Colitis Through 18F-FDG PET/CT During the Restaging of Colorectal Cancer
Kolorektal Kanserin Erevlenmesi Sırasında 18F-FDG PET/IBT ile Psödomembranöz Kollitin Tesadüfen Saptanması
Luca Filippi; Latina, Italy

74  A Rare Case and Atypical Metastatic Regions, Pulmonary Giant Cell Carcinoma
Nadir Olgu ve Atipik Metastatik Bölgeler, Pulmoner Dev Hücreli Karsinom
Ceyda Nur Dündar Çağlayan, Müge Nur Engin, Adil Boz; Antalya, Turkey

77  Snow Leopard Appearance of Subcutaneous Panniculitis such as T-cell Lymphoma on 18F-FDG PET/CT
18F-FDG PET/CT’de T-hücreli Lenfoma Benzeri Alb Pannikülitin Kar Leopari Görünümü
Salah Nabih Ouergiiali, Laila El Asraoui, Omar Ait Sahel, Yassir Benenameur, Abderrahim Doudouh; Rabat, Morocco

80  Significance of Clinico-radiological Correlation in a Patient with Pulmonary Intimal Sarcoma Simulating as Pulmonary Thromboembolism
Pulmoner Tromboembolizmi Takltd Eden Pulmoner Intimal Sarkomlu Bir Hastada Klinik-radyolojik Korelasyonun Önemi
Stuti Chandola, Ekta Dhamija, Sameer Rastogi, Deepali Jain; New Delhi, India

83  Primary Isolated Breast Lymphoma Presenting as Primary Breast Cancer with 18F-FDG PET/CT
18F-FDG PET/IBT’de Meme Karserinini Takltd Eden Primer Meme Lenfoması
Özge Vural Topuz, Özgür Omak, Bürak Yılmaz; İstanbul, Turkey

87  A Rare Hernia Mimicking Implant in a Patient with Rectal Adenocarcinoma: Internal Herniation
Rektal Adenokarsinomlu Bir Hastada Implantı Takltd Eden Nadir Bir Fitik: Internal Herniasyon
Sibel Gökşel, Mustafa Başaran, Hasan Gündoğdu, Cengiz Karaçin; Ankara, Turkey

Case Report
90  18F-FDG PET/CT Findings Overlapping Lymphoma in a Patient with Systemic Juvenile Idiopathic Arthritis
Sistemik Jüvenil İdiyopatik Artritli Bir Hastada Lenfoma ile Örtüşen 18F-FDG PET/IBT Bulguları
Özlem Şahin, Bülent Ataş, Özge Metin Akcan, Ahmet Eren Şen; Konya, Turkey